Advertisement

Newer Oral Anticoagulants

  • Ravul Jindal
  • Piyush Chaudhary
Chapter

Abstract

Thrombos is in veins and arteries are treated with the help of anticoagulants. They can be given either by parenteral or oral route. Before we use to have only vitamin K antagonists (VKAs), such as warfarin and Acitrom which are very useful and effective but have lots of limitations, which complicate its management. This led to discovery of newer oral anticoagulants (NOACs) which were more patient friendly. These agents inhibit thrombin and factor Xa. As vitamin K intake has no effect on the activity of the NOACs, these drugs produced a more predictable anticoagulant response than vitamin K antagonists. They also had less drug-drug interactions. These drugs have totally changed the way we treat the patients suffering from thrombosis.

References

  1. 1.
    Jeffrey I, Weitz F. Expanding use of new oral anticoagulants. 1000 Prime Rep. 2014;6:93.  https://doi.org/10.12703/P6-93.CrossRefGoogle Scholar
  2. 2.
    Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Blackwell Publishing Ltd. Br J Hematol. 2008;141:757–63.CrossRefGoogle Scholar
  3. 3.
    Mannucci PM, Poller L. Venous thrombosis and anticoagulant therapy. Br J Haematol. 2001;114(2):258–70.  https://doi.org/10.1046/j.1365-2141.2001.02961.CrossRefPubMedGoogle Scholar
  4. 4.
    Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Chest. 2012;141(2):e691S–736S.CrossRefGoogle Scholar
  5. 5.
    Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61–75.CrossRefGoogle Scholar
  6. 6.
    Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy. Chest. 2012;141(2):e44S–88S.CrossRefGoogle Scholar
  7. 7.
    van Ryn J, Goss A, Hauel N, Wienen W, Priepke H, Nar H, Clemens A. The discovery of dabigatran etexilate. Front Pharmacol. 2013;4:12.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Hanna MS, Mohan P, Knabb R, Gupta E, Frost C, Lawrence JH. Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Ann N Y Acad Sci. 2014;1329(1):93–106.CrossRefGoogle Scholar
  9. 9.
    Roca B, Roca M. The new oral anticoagulants: reasonable alternatives to warfarin. Cleve Clin J Med. 2015;82(12):847–54.CrossRefGoogle Scholar
  10. 10.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Peter S, John Camm A, Kirchhof P. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefGoogle Scholar
  11. 11.
    Dabbous MK, Malaeb DN, Sakr FR. Anticoagulant therapy in pediatrics. J Basic Clin Pharm. 2014;5(2):27.CrossRefGoogle Scholar
  12. 12.
    Mekaj A, Mekaj Y, Duci S, Miftari E. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967.CrossRefGoogle Scholar
  13. 13.
    Masotti L, Pampanini M. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. Ital J Med. 2013;7(8S):1–7.  https://doi.org/10.4081/itjm.s8.1.
  14. 14.
    Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Christopher G, Magnus Ohman E, Dalen JE. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(1):64S–94S.CrossRefGoogle Scholar
  15. 15.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.CrossRefGoogle Scholar
  16. 16.
    Wong PC, Pinto DJP, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478–92.CrossRefGoogle Scholar
  17. 17.
    Dolgin E. Antidotes edge closer to reversing effects of new blood thinners. Nat Med. 2013;19(3):251.CrossRefGoogle Scholar
  18. 18.
    Hinojar R, Jiménez-Natcher JJ, Fernández-Golfín C, Zamorano JL. New oral anticoagulants: a practical guide for physicians. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):134–45.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Ravul Jindal
    • 1
  • Piyush Chaudhary
    • 1
  1. 1.Vascular and Endovascular SurgeryFortis HospitalMohaliIndia

Personalised recommendations